[o2–17–06]: safety and tolerability of crenezumab in mild‐to‐moderate ad patients treated with escalating doses for up to 25 monthsVeronica Asnaghi,Helen Lin,Nan Hu,Jillian Smith,William Cho,Susanne OstrowitzkiAlzheimer's & Dementia（2017）引用 2|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
